CCNE1 and ovarian carcinoma: A study in BRCAwt, CCNE1 amplified platinum-resistant ovarian cancer patient-derived xenograft (PDX) models showed that the combination of PARPi and ATRi results in tumor reduction and a significant increase in OS[98].